Immutep Lost Most of Its Value in a Single Day. Here's Why.

To be clear, no specific numbers (hazard ratios, p-values, or survival curves) have been disclosed yet. Immutep may present detailed results at a future medical congress. But the signal was bad enough for the IDMC to recommend stopping entirely, and that tells you plenty.

What makes this especially painful is that earlier data looked genuinely promising. But Phase 3 trials are the ultimate reality check. Promising early results don't always hold up when tested in larger, more diverse patient populations with rigorous controls. It's the difference between acing a practice exam and bombing the final.

Wall Street's Brutal Reaction

The stock market showed zero mercy. Immutep shares (ASX: IMM) had been trading around A$0.395 just days before the announcement. On March 13, they closed at A$0.05, with intraday lows touching A$0.03. Trading volume exploded to 432 million shares as investors stampeded for the exits.

Analysts scrambled to downgrade. Baird's Colleen Kusy cut the stock from Outperform to Neutral and slashed her price target from $7.00 to $1.00. Citizens analyst Reni Benjamin also downgraded, removing all NSCLC revenue projections from his model entirely.

CEO Marc Voigt expressed disappointment, noting that efti had shown promising results in other clinical settings. He also pointed out that the company's cash runway extends beyond Q2 2027, a way of saying: "We're not dead yet."

A Bad Year Gets Worse for Immunotherapy Gamblers

Immutep's failure doesn't exist in a vacuum. The immunotherapy sector has been littered with late-stage casualties recently. The TIGIT pathway, once considered the next big checkpoint target, has been a graveyard. iTeos Therapeutics saw belrestotug fail in Phase 2 trials in lung and head and neck cancers, leading to a halt in Phase 3 enrollment. Roche saw back-to-back Phase 3 losses with tiragolumab in NSCLC. Merck and Bristol Myers Squibb have also stumbled targeting TIGIT.

The pattern is troubling: drugs that look great in early trials keep falling apart in the big, definitive studies. Nearly 46% of recent Phase 3 neurology trials started without positive Phase 2 data, according to a recent analysis, and those trials had only a 31% positive outcome rate compared to 57% for trials built on solid earlier evidence.

What's Left in the Tank?

The LAG-3 target itself isn't dead. Bristol-Myers Squibb's Opdualag (relatlimab plus nivolumab), which blocks LAG-3 rather than activating through it like efti does, is already approved for metastatic melanoma. Market forecasts project the LAG-3 immunotherapy space growing from roughly $588 million in 2025 to over $6 billion by 2035.

But Immutep's specific approach, using a soluble LAG-3 protein to boost the immune system's scouts rather than block an inhibitory signal, just took a massive credibility hit. The company still has earlier-stage programs, including a Phase 2 trial (TACTI-003) in head and neck cancer. Whether investors have the patience to stick around for those readouts is another question entirely.

For a company that lost most of its value in a day, "patience" might be a lot to ask. Sometimes the gas pedal works perfectly fine; it's just hooked up to the wrong engine.

Vertex Bet $5 Billion on a Kidney Drug. It Just Paid Off.

Vertex dropped $4.9 billion on a kidney drug most people had never heard of. Two years later, the Phase 3 data just landed, and it's turning heads across the IgA nephropathy space. The stock hit a record high.